Triple

T184502
Position Surface form Disambiguated ID Type / Status
Subject European Medicines Agency E3950 entity
Predicate hasCommittee P1396 FINISHED
Object Pharmacovigilance Risk Assessment Committee
The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of medicines and managing pharmacovigilance activities within the European Union.
E3950 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Pharmacovigilance Risk Assessment Committee | Statement: [European Medicines Agency, hasCommittee, Pharmacovigilance Risk Assessment Committee]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Pharmacovigilance Risk Assessment Committee
Context triple: [European Medicines Agency, hasCommittee, Pharmacovigilance Risk Assessment Committee]
  • A. European Directorate for the Quality of Medicines & HealthCare
    The European Directorate for the Quality of Medicines & HealthCare is a Council of Europe body responsible for developing quality standards and guidance to ensure the safety and efficacy of medicines and improve healthcare across member states.
  • B. European Medicines Agency
    The European Medicines Agency is the European Union’s regulatory authority responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use.
  • C. UK Medicines and Healthcare products Regulatory Agency
    The UK Medicines and Healthcare products Regulatory Agency is the United Kingdom’s national authority responsible for regulating medicines, medical devices, and healthcare products to ensure their safety, quality, and effectiveness.
  • D. Facilitation Committee
    The Facilitation Committee is a specialized body within the International Maritime Organization responsible for simplifying and harmonizing international maritime trade procedures and documentation.
  • E. WHO Emergency Committee
    The WHO Emergency Committee is a group of international public health experts convened by the World Health Organization to assess serious disease outbreaks and advise on whether they constitute a global health emergency.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Pharmacovigilance Risk Assessment Committee
Triple: [European Medicines Agency, hasCommittee, Pharmacovigilance Risk Assessment Committee]
Generated description
The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of medicines and managing pharmacovigilance activities within the European Union.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Pharmacovigilance Risk Assessment Committee
Target entity description: The Pharmacovigilance Risk Assessment Committee is a scientific body responsible for evaluating and monitoring the safety of medicines and managing pharmacovigilance activities within the European Union.
  • A. European Directorate for the Quality of Medicines & HealthCare
    The European Directorate for the Quality of Medicines & HealthCare is a Council of Europe body responsible for developing quality standards and guidance to ensure the safety and efficacy of medicines and improve healthcare across member states.
  • B. European Medicines Agency chosen
    The European Medicines Agency is the European Union’s regulatory authority responsible for the scientific evaluation, supervision, and safety monitoring of medicines for human and veterinary use.
  • C. UK Medicines and Healthcare products Regulatory Agency
    The UK Medicines and Healthcare products Regulatory Agency is the United Kingdom’s national authority responsible for regulating medicines, medical devices, and healthcare products to ensure their safety, quality, and effectiveness.
  • D. Facilitation Committee
    The Facilitation Committee is a specialized body within the International Maritime Organization responsible for simplifying and harmonizing international maritime trade procedures and documentation.
  • E. WHO Emergency Committee
    The WHO Emergency Committee is a group of international public health experts convened by the World Health Organization to assess serious disease outbreaks and advise on whether they constitute a global health emergency.
  • F. None of above.

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a25497e2f08190a040f8c6e1842643 completed Feb. 28, 2026, 2:36 a.m.
NER Named-entity recognition batch_69a25926be9c8190a4cfce66f57589d1 completed Feb. 28, 2026, 2:55 a.m.
NED1 Entity disambiguation (via context triple) batch_69a2fd0577588190a91be504e3c9f0ab completed Feb. 28, 2026, 2:34 p.m.
NEDg Description generation batch_69a2fe0b1c148190854569c3f6e03a91 completed Feb. 28, 2026, 2:39 p.m.
NED2 Entity disambiguation (via description) batch_69a2fe7676488190b0d126a7d3d75b5f completed Feb. 28, 2026, 2:40 p.m.
Created at: Feb. 28, 2026, 2:40 a.m.